Form 8-K Crinetics Pharmaceutical For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 dips after Trump says Iran deal is 'over'
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Stifel Downgrades Crinetics (CRNX) to Hold
July 8, 2026 8:45 AM EDTStifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).
The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25,... More
